When MIC Alone Is Not Enough

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

MIC predicts drug potency in broth, but clinical success depends on pharmacokinetic and pharmacodynamic factors that standard susceptibility testing does not measure.
When a susceptible result conflicts with observed treatment failure, evaluate protein binding, tissue penetration, and resistant subpopulations before changing therapy.
No single laboratory value predicts clinical outcome, and PK/PD discordance requires case-by-case interpretation with infectious disease consultation.

At a Glance

Discordance Cause	What MIC Misses	Practical Assessment Step
Protein binding	Only free drug exerts antimicrobial effect	Review drug protein-binding percentage and compare with dosing interval
Tissue penetration	MIC measures serum activity, not infection-site concentration	Confirm infection site and evaluate drug distribution characteristics
Mutant subpopulations	MIC reflects dominant population, not resistant subclones	Request population analysis or review resistance mechanism data
Inoculum effect	High bacterial density reduces apparent drug activity	Review culture source and bacterial load estimates
pH and anaerobic conditions	Local environment alters drug activity	Consider infection site conditions such as abscess or biofilm
Host immune status	MICRO does not measure host contribution	Assess patient immune function and infection severity

Understanding the MICRO-PK/PD Discordance Problem

Minimum inhibitory concentration testing remains the foundational tool for antimicrobial susceptibility assessment in clinical microbiology. The Clinical and Laboratory Standards Institute publishes standardized methods that laboratories use to determine whether a bacterial isolate is susceptible, intermediate, or resistant to a given antimicrobial agent. These standards ensure that testing conditions are reproducible and that results can be interpreted consistently across different laboratories.

The MICRO value represents the lowest concentration of an antimicrobial agent that visibly inhibits bacterial growth under standardized in vitro conditions. This measurement provides a useful baseline for comparing antimicrobial activity against a specific pathogen. However, the MICRO does not account for the dynamic relationship between drug concentrations in the human body over time and the antimicrobial effect at the site of infection.

Pharmacokinetics describes what the body does to a drug, including absorption, distribution, metabolism, and elimination. Pharmacodynamics describes what the drug does to the body, specifically the relationship between drug concentration and antimicrobial effect. The integration of these two disciplines, known as PK/PD, provides a more complete picture of whether a particular antimicrobial regimen will achieve clinical success.

The discordance between MICRO and PK/PD predictions arises when the in vitro susceptibility result does not align with the expected clinical outcome. A pathogen may appear susceptible by MICRO testing, yet therapy fails because the drug does not reach adequate concentrations at the infection site. Conversely, a pathogen may appear resistant by MICRO testing, yet therapy succeeds because the drug concentrates at the infection site or because the host immune system contributes to bacterial clearance.

This discordance is not a laboratory error. It reflects the fundamental difference between a controlled in vitro environment and the complex conditions of an infected human host. Understanding the sources of this discordance is essential for clinicians and microbiologists who must interpret susceptibility results in the context of individual patient care.

Pharmacokinetic Factors That Alter Drug Exposure

Protein Binding and Free Drug Concentrations

Many antimicrobial agents bind to serum proteins, particularly albumin, when they enter the bloodstream. The bound fraction is pharmacologically inactive because it cannot interact with bacterial targets. Only the unbound, free fraction of the drug exerts antimicrobial activity.

The MICRO is determined in culture media that typically contains minimal protein. This means the MICRO reflects the activity of the total drug concentration, not the free concentration that would be available in human serum. For drugs with high protein binding, the free concentration in serum may be substantially lower than the total concentration, leading to a situation where the MICRO suggests susceptibility but the actual active drug concentration is insufficient.

Highly protein-bound antimicrobial agents include certain cephalosporins, tetracyclines, and rifamycins. The clinical significance of protein binding depends on the extent of binding and the margin between the free drug concentration and the MICRO. For drugs with moderate protein binding, the difference may be clinically negligible. For drugs with very high protein binding, the difference can be substantial and may require dose adjustment or alternative therapy.

The free drug concentration is also affected by conditions that alter serum protein levels. Patients with hypoalbuminemia, such as those with critical illness, liver disease, or malnutrition, may have higher free drug concentrations than expected. Conversely, patients with elevated protein levels may have lower free drug concentrations. These variations are not captured by standard MICRO testing and require clinical awareness.

Volume of Distribution and Tissue Penetration

The MICRO measures drug activity in a standardized broth medium, not in the tissue where the infection is located. Antimicrobial agents distribute differently across body compartments based on their physicochemical properties. Lipophilic drugs tend to penetrate tissues well, while hydrophilic drugs may remain primarily in the extracellular space.

For infections in tissues that are difficult to penetrate, such as the central nervous system, bone, or abscess cavities, the drug concentration at the infection site may be substantially lower than the serum concentration. The blood-brain barrier restricts the entry of many antimicrobial agents into the cerebrospinal fluid. Similarly, the blood-prostate barrier limits drug penetration into prostatic tissue. Abscess cavities have poor vascularity and may contain pus that binds or inactivates antimicrobial agents.

The MICRO does not account for these distribution barriers. A drug may have a low MICRO against a pathogen, but if it cannot reach the infection site in adequate concentrations, therapy will fail. This is particularly relevant for infections in sequestered sites where drug penetration is limited.

Drug Metabolism and Elimination

The rate at which a drug is eliminated from the body affects the duration of time that drug concentrations remain above the MICRO. Drugs with short half-lives require more frequent dosing or continuous infusion to maintain adequate concentrations. Drugs with long half-lives may accumulate and cause toxicity if dosing intervals are not adjusted.

Renal and hepatic function significantly influence drug elimination. Patients with renal impairment may accumulate drugs that are renally excreted, leading to toxicity. Patients with hepatic impairment may have reduced metabolism of hepatically cleared drugs, also leading to accumulation. The MICRO does not account for these patient-specific factors.

The pharmacodynamic index that best predicts clinical efficacy depends on the drug class. For concentration-dependent agents, the ratio of peak concentration to MICRO is the best predictor. For time-dependent agents, the percentage of the dosing interval during which the drug concentration remains above the MICRO is the best predictor. For agents with prolonged post-antibiotic effects, the area under the concentration-time curve relative to the MICRO may be most relevant.

Pharmacodynamic Factors That Influence Clinical Response

Concentration-Dependent versus Time-Dependent Killing

Antimicrobial agents can be classified by the relationship between drug concentration and bacterial killing. Concentration-dependent agents, such as aminoglycosides and fluoroquinolones, kill bacteria more rapidly as the drug concentration increases. The clinical efficacy of these agents is best predicted by the ratio of the peak drug concentration to the MICRO or the ratio of the area under the concentration-time curve to the MICRO.

Time-dependent agents, such as beta-lactams and vancomycin, kill bacteria at a relatively constant rate once the drug concentration exceeds the MICRO. The clinical efficacy of these agents is best predicted by the percentage of the dosing interval during which the drug concentration remains above the MICRO. For these agents, maintaining adequate drug concentrations throughout the dosing interval is more important than achieving high peak concentrations.

The MICRO alone does not indicate which pharmacodynamic index is most relevant for a given drug. The same MICRO value can be associated with different clinical outcomes depending on the drug class and the dosing regimen. A beta-lactam with a low MICRO may fail if the dosing interval is too long and drug concentrations fall below the MICRO for a substantial portion of the interval. An aminoglycoside with a higher MICRO may succeed if the peak concentration is sufficiently high.

Post-Antibiotic Effect

The post-antibiotic effect is the persistent suppression of bacterial growth after the drug concentration falls below the MICRO. This effect varies by drug class and bacterial species. Aminoglycosides and fluoroquinolones exhibit prolonged post-antibiotic effects against many gram-negative bacteria. Beta-lactams generally have short or absent post-antibiotic effects against gram-negative bacteria but may have longer effects against gram-positive bacteria.

The post-antibiotic effect allows for longer dosing intervals without loss of efficacy. A drug with a prolonged post-antibiotic effect can be dosed less frequently because the bacterial suppression continues even when drug concentrations fall below the MICRO. The MICRO does not capture this effect, and the clinical relevance of the post-antibiotic effect is not reflected in standard susceptibility testing.

Inoculum Effect and Bacterial Burden

The MICRO can be influenced by the size of the bacterial inoculum used in the test. Standard susceptibility testing uses a standardized inoculum, typically 5 x 10^5 colony-forming units per milliliter. However, the bacterial burden at the infection site may be substantially higher, particularly in abscesses, endocarditis vegetations, or infected foreign bodies.

Some antimicrobial agents exhibit an inoculum effect, where the MICRO increases as the bacterial inoculum increases. This is particularly relevant for beta-lactams and certain other agents. The clinical implication is that a drug may appear effective against a low bacterial burden but fail against a high bacterial burden because the effective MICRO is higher than the standard test suggests.

The inoculum effect is not captured by standard MICRO testing. When a patient has a high bacterial burden, the clinician must consider whether the drug will be effective at the actual infection site. This may require higher doses, combination therapy, or surgical drainage to reduce the bacterial burden.

Mutant Subpopulations and Heteroresistance

The Role of Resistant Subpopulations

Bacterial populations are not always homogeneous. A clinical isolate may contain a mixture of susceptible and resistant subpopulations. Standard MICRO testing measures the susceptibility of the dominant population, which may not reflect the presence of a small but clinically significant resistant subpopulation.

Heteroresistance occurs when a bacterial population contains subpopulations with different susceptibility levels. The MICRO may indicate susceptibility because the dominant population is susceptible, but the resistant subpopulation can emerge during therapy and cause treatment failure. This phenomenon has been described for various antimicrobial agents, including vancomycin and colistin.

The clinical significance of heteroresistance depends on the size of the resistant subpopulation and the drug concentration achieved at the infection site. If the drug concentration exceeds the MICRO of the resistant subpopulation, the resistant bacteria may still be inhibited. If the drug concentration is below the MICRO of the resistant subpopulation, the resistant bacteria can proliferate and cause clinical failure.

Standard MICRO testing does not detect heteroresistance because it measures the overall population response. Population analysis profiles or other specialized methods are needed to identify resistant subpopulations. These methods are not routinely performed in clinical laboratories and may require referral to a specialized laboratory.

Biofilm-Associated Tolerance

Bacteria growing in biofilms exhibit a different susceptibility profile than planktonic bacteria. Biofilms are communities of bacteria attached to surfaces and embedded in a matrix of extracellular polymeric substances. Bacteria in biofilms can be substantially less susceptible to antimicrobial agents than the same bacteria growing in planktonic culture.

The reduced susceptibility of biofilm-associated bacteria is not due to genetic resistance but to the physiological state of the bacteria and the physical barrier created by the biofilm matrix. Bacteria in biofilms may be in a slow-growing or dormant state that makes them less susceptible to antimicrobial agents that target actively growing cells. The biofilm matrix can also limit the penetration of antimicrobial agents.

Standard MICRO testing uses planktonic bacteria and does not reflect the susceptibility of biofilm-associated bacteria. This is particularly relevant for infections such as prosthetic joint infections, catheter-associated infections, and endocarditis, where biofilms are common. The MICRO may suggest that an antimicrobial agent is effective, but the agent may fail to eradicate the biofilm-associated infection.

Laboratory Factors That Can Confound MICRO Results

Testing Conditions and Media

The MICRO is determined under standardized conditions that may not reflect the conditions at the infection site. The pH of the testing medium, the cation concentration, and the presence of other substances can affect the MICRO. For example, the MICRO of aminoglycosides is affected by the cation concentration of the testing medium. The MICRO of macrolides can be affected by the pH of the medium.

The Clinical and Laboratory Standards Institute provides standardized methods for antimicrobial susceptibility testing to ensure consistency across laboratories. These standards specify the testing medium, the inoculum size, the incubation conditions, and the interpretation criteria. However, these standardized conditions may not reflect the conditions at the infection site, where pH, oxygen tension, and other factors can differ.

The discordance between the MICRO and the clinical outcome can arise when the infection site conditions differ substantially from the standardized testing conditions. For example, an abscess may have a low pH and low oxygen tension, which can affect the activity of certain antimicrobial agents. The MICRO determined under standard conditions may not predict the activity of the drug in the abscess environment.

Laboratory Quality and Authenticated Strains

The accuracy of MICRO testing depends on the quality of the laboratory procedures and the use of appropriate quality control strains. The Clinical and Laboratory Standards Institute provides guidelines for quality control in antimicrobial susceptibility testing. The American Type Culture Collection provides authenticated biological materials, including quality control strains, that are used to verify the accuracy of susceptibility testing.

Laboratories must use authenticated reference strains to ensure that their testing procedures are working correctly. The use of unauthenticated or contaminated strains can produce inaccurate MICRO results. The American Society for Microbiology provides professional education and laboratory practice resources that support the quality of microbiology testing.

The accuracy of MICRO testing also depends on the skill and experience of the laboratory personnel. Errors in inoculum preparation, incubation conditions, or interpretation can lead to inaccurate MICRO results. The American Society for Microbiology provides professional education and workforce development resources that support the competence of microbiology laboratory professionals.

Practical Workflow for Resolving MICRO-PK/PD Discordance

Step 1: Verify the Susceptibility Result

When a patient fails therapy despite a susceptible MICRO result, the first step is to verify the accuracy of the susceptibility result. Review the laboratory report for any errors in identification or susceptibility testing. Confirm that the correct organism was tested and that the MICRO was determined using appropriate methods.

Check the quality control data for the testing period to ensure that the laboratory procedures were working correctly. The Clinical and Laboratory Standards Institute provides guidelines for quality control in antimicrobial susceptibility testing. If the quality control results were within acceptable ranges, the MICRO result is likely accurate.

Consider whether the organism identification is correct. Misidentification can lead to incorrect susceptibility interpretation. The American Society for Microbiology provides resources for the identification of bacteria and the interpretation of susceptibility results.

Step 2: Assess the Pharmacokinetic Profile

If the MICRO result is accurate, the next step is to assess whether the drug can achieve adequate concentrations at the infection site. Review the drug dosing, the route of administration, and the patient-specific factors that affect drug distribution and elimination.

Consider the protein binding of the drug and whether the free drug concentration is adequate. Consider the volume of distribution and whether the drug penetrates the infection site. Consider the patient's renal and hepatic function and whether the drug elimination is altered.

The drug concentration at the infection site may be measured in some cases. Therapeutic drug monitoring can be used to measure drug concentrations in serum or other fluids. The measured concentration can be compared with the MICRO to determine whether the drug concentration is adequate.

Step 3: Evaluate the Infection Site and Host Factors

The infection site can affect the activity of antimicrobial agents. Consider whether the infection is in a sequestered site, such as the central nervous system, bone, or an abscess. Consider whether the infection is associated with a biofilm, such as a prosthetic infection or a catheter infection.

Consider the host immune status. The immune system contributes to the clearance of infection, and an immunocompromised patient may require higher drug concentrations or longer therapy. The MICRO does not account for the host contribution to bacterial clearance.

Consider the bacterial burden at the infection site. A high bacterial burden may require higher drug concentrations or additional interventions, such as surgical drainage. The inoculum effect may be relevant for certain antimicrobial agents.

Step 4: Consider Alternative Explanations

If the MICRO result is accurate and the drug concentrations appear adequate, consider alternative explanations for the treatment failure. The patient may have a different pathogen than the one identified. The infection may be caused by a mixed bacterial population. The patient may have a foreign body or other source of infection that requires removal.

Consider the possibility of heteroresistance or the emergence of resistance during treatment. The resistant subpopulation may not have been detected by the initial susceptibility testing. Consider the possibility of a superinfection with a different pathogen.

Step 5: Escalate to Clinical Consultation

If the discordance between the MICRO and the clinical outcome cannot be resolved, escalate to a clinical consultation. An infectious disease specialist can provide guidance on the interpretation of the susceptibility results and the selection of alternative therapy. A clinical pharmacist can provide guidance on drug dosing and the optimization of the pharmacokinetic profile.

The decision to change therapy should be based on the clinical status of the patient and the likelihood of clinical success with the current regimen. The MICRO is one piece of information that should be considered in the context of the patient's clinical presentation, the infection site, and the host factors.

Records and Measurements for Clinical Decision-Making

Documenting the MICRO and PK/PD Assessment

The clinical decision to continue or change antimicrobial therapy should be documented in the patient record. The documentation should include the MICRO result, the drug dosing, the infection site, and the clinical response. The documentation should also include the rationale for the decision, including any PK/PD considerations.

The documentation should be clear and concise, and it should be accessible to other clinicians who are involved in the patient's care. The documentation should include the date and time of the assessment, the name of the clinician, and the plan for follow-up.

Monitoring the Clinical Response

The clinical response to antimicrobial therapy should be monitored regularly. The monitoring should include the patient's temperature, white blood cell count, and other markers of infection. The monitoring should also include the clinical signs and symptoms of the infection, such as pain, swelling, or discharge.

The clinical response should be assessed at regular intervals, and the therapy should be adjusted if the response is not adequate. The MICRO result should be reviewed in the context of the clinical response, and the PK/PD considerations should be reassessed if the response is not adequate.

Recording the Outcome

The outcome of the therapy should be recorded in the clinical record. The outcome should include whether the infection resolved, whether the therapy was changed, and whether the patient experienced any adverse effects. The outcome should also include any follow-up cultures or susceptibility testing.

The recording of the outcome is important for the quality improvement of antimicrobial therapy. The outcome data can be used to identify patterns of treatment failure and to improve the selection of antimicrobial therapy in the future.

Common Failure Patterns and Their Resolution

Pattern 1: Susceptible MICRO with Clinical Failure

The most common pattern is a susceptible MICRO result with clinical failure. This pattern suggests that the drug is not achieving adequate concentrations at the infection site or that the infection is not responding to the drug for another reason.

The resolution of this pattern requires a review of the drug dosing, the infection site, and the host factors. The drug dose may need to be increased, the route of administration may need to be changed, or the drug may need to be changed to an alternative agent.

Pattern 2: Resistant MICRO with Clinical Success

The less common pattern is a resistant MICRO result with clinical success. This pattern may occur when the drug achieves high concentrations at the infection site, when the host immune system contributes to the clearance of the infection, or when the resistant result is not clinically significant.

The resolution of this pattern requires a review of the drug concentrations and the clinical response. The drug may be continued if the clinical response is adequate, but the patient should be monitored for the emergence of resistance.

Pattern 3: Discordance between MICRO and Clinical Outcome

The discordance between the MICRO and the clinical outcome may be due to a variety of factors, including the pharmacokinetic profile, the infection site, the host factors, or the bacterial population. The resolution of this pattern requires a systematic review of the factors that can affect the clinical outcome.

The systematic review should include the verification of the MICRO result, the assessment of the drug concentrations, the evaluation of the infection site, and the consideration of the host factors. The review should be documented in the clinical record, and the decision should be made in the context of the clinical status of the patient.

Biosafety and Laboratory Considerations

Handling of Clinical Isolates

The handling of clinical isolates requires adherence to biosafety principles. The Biosafety in Microbiological and Biomedical Laboratories provides guidelines for the safe handling of microorganisms in the laboratory. The guidelines include the use of appropriate containment, personal protective equipment, and decontamination procedures.

The laboratory should have a biosafety plan that addresses the risks associated with the handling of clinical isolates. The plan should include the procedures for the safe handling of specimens, the decontamination of work surfaces, and the disposal of waste. The laboratory should also have procedures for the reporting of laboratory-acquired infections.

Quality Control and Authenticated Strains

The quality control of antimicrobial susceptibility testing requires the use of authenticated reference strains. The American Type Culture Collection provides authenticated biological materials that are used for quality control. The quality control strains should be used to verify the accuracy of the testing procedures.

The laboratory should maintain a record of the quality control results and the reference strains used. The quality control results should be reviewed regularly to ensure that the testing procedures are working correctly. The American Society for Microbiology provides the guidance and resources for the quality control of microbiology laboratory.

Decontamination and Waste Management

The decontamination of laboratory waste is an important part of the biosafety program. The Biosafety in Microbiological and Biomedical Laboratories provides guidelines for the decontamination of laboratory waste. The guidelines should be followed to ensure that the waste is decontaminated before disposal.

The laboratory should have a waste management plan that addresses the collection, decontamination, and disposal of laboratory waste. The plan should include the procedures for the decontamination of the waste, the use of appropriate containers, and the disposal of the waste. The laboratory should also include the procedures for the decontamination of the work surfaces and the equipment.

Limitations of MICRO and PK/PD Predictions

The MICRO Is a Static Measure

The MICRO is a static measure that does not capture the dynamic relationship between drug concentrations and bacterial growth over time. The MICRO is determined at a single time point, and it does not reflect the changes in drug concentrations that occur over the dosing interval. The PK/PD predictions provide a more realistic picture of the dynamic relationship between drug concentrations and bacterial growth.

The MICRO also does not capture the effect of the drug on the bacterial population over time. The MICRO measures the inhibition of bacterial growth, but it does not measure the killing of the bacteria. The bactericidal activity of the drug may be more important than the bacteriostatic activity for certain infections.

The PK/PD Predictions Are Model-Based

The PK/PD predictions are based on mathematical models that may not capture the complexity of the clinical situation. The models are based on the drug concentrations and the MICRO, but they may not account for the host factors, the infection site, or the bacterial population. The models may also not account for the variability in the drug concentrations between patients.

The PK/PD predictions should be used as a guide for the selection of antimicrobial therapy, but they should not be used as the sole basis for the decision. The clinical status of the patient, the infection site, and the host factors should be considered in the context of the PK/PD predictions.

The Clinical Outcome is Multifactorial

The clinical outcome of an antimicrobial therapy is determined by a variety of factors, including the drug, the pathogen, the host, and the infection site. The MICRO and the PK/PD predictions are only two of the factors that determine the clinical outcome. The clinical outcome may be affected by the host immune status, the presence of a foreign body, the bacterial burden, and the patient's underlying medical conditions.

The clinical outcome should be assessed in the context of the patient's clinical presentation and the infection site. The MICRO and the PK/PD predictions should be used as a guide, but the clinical decision should be based on the overall clinical picture.

Professional Escalation Criteria

When to Consult an Infectious Disease Specialist

The clinical decision to change antimicrobial therapy should be made in the context of the patient's clinical status. If the patient is not responding to the current therapy, the clinical team should consider the consultation of an infectious disease specialist. The specialist can provide guidance on the interpretation of the MICRO and the PK/PD predictions, and the selection of alternative therapy.

The consultation should be considered when the patient has a severe infection, when the infection is not responding to the current therapy, or when the infection is caused by a resistant pathogen. The consultation should also be considered when the patient has a complex medical history or when the infection is at a difficult site.

When to Seek a Clinical Microbiology Consultation

The clinical microbiology consultation should be considered when the MICRO result is discordant with the clinical outcome. The microbiologist can provide guidance on the interpretation of the susceptibility result, the identification of the organism, and the selection of alternative therapy.

The consultation should be considered when the laboratory result is uncertain, when the organism is difficult to identify, or when the susceptibility result is not consistent with the clinical picture. The microbiologist can also provide guidance on the use of specialized testing, such as the detection of heteroresistance or the testing of the biofilm susceptibility.

When to Escalate to the Public Health Authority

The escalation to the public health authority should be considered when the infection is caused by a pathogen that is a public health concern. The World Health Organization provides the global context for antimicrobial resistance and the surveillance of resistant pathogens. The public health authority should be notified when the infection is caused by a resistant pathogen that is not responding to the therapy.

The escalation should also be considered when the infection is caused by a pathogen that is not commonly seen in the clinical setting, or when the infection is associated with a public health concern. The public health authority can provide guidance on the management of the infection and the surveillance of the resistant pathogen.

Frequently Asked Questions

What does MICRO measure and what does it not measure?

MICRO measures the lowest concentration of an antimicrobial agent that inhibits bacterial growth under standardized in vitro conditions. It does not measure the drug concentrations in the patient, the drug distribution to the infection site, the host immune response, or the bacterial population dynamics. The MICRO is a static measure that does not capture the dynamic relationship between drug concentrations and bacterial growth over time.

Why does a patient fail therapy when the MICRO is susceptible?

A patient may fail therapy despite a susceptible MICRO because the drug cannot achieve adequate concentrations at the infection site. The drug may be highly protein-bound, the drug may not penetrate the infection site, or the drug may be eliminated too quickly. The infection site may also have a high bacterial burden, a biofilm, or a low pH that reduces the drug activity.

What is the difference between concentration-dependent and time-dependent killing?

Concentration-dependent killing occurs when the rate of bacterial killing increases with the drug concentration. The clinical efficacy of concentration-dependent drugs is best predicted by the ratio of the peak concentration to the MICRO or the ratio of the area under the concentration-time curve to the MICRO. Time-dependent killing occurs when the rate of bacterial killing is relatively constant once the drug concentration exceeds the MICRO. The clinical efficacy of time-dependent drugs is best predicted by the time the drug concentration remains above the MICRO.

How does protein binding affect the MICRO?

The MICRO is determined in a medium that typically contains no protein, so it measures the activity of the total drug concentration. In the patient, the drug binds to serum proteins, and only the free drug fraction is active. For drugs with high protein binding, the free drug concentration may be substantially lower than the total concentration, leading to a situation where the MICRO suggests susceptibility but the actual free drug concentration is inadequate.

What is the inoculum effect and why does it matter?

The inoculum effect occurs when the MICRO increases as the bacterial inoculum increases. Standard susceptibility testing uses a fixed inoculum, but the bacterial burden at the infection site may be much higher. The inoculum effect is particularly relevant for certain antimicrobial agents and for infections with a high bacterial burden, such as abscesses or endocarditis. The clinical implication is that a drug may appear effective against a low bacterial burden but fail against a high bacterial burden.

What is heteroresistance and how does it affect therapy?

Heteroresistance occurs when a bacterial population contains subpopulations with different susceptibility to an antimicrobial agent. The MICRO reflects the dominant population, but the resistant subpopulation can emerge during treatment and cause failure. Heteroresistance is not detected by standard susceptibility testing and may require specialized methods such as population analysis profiles.

How do biofilms affect the MICRO and clinical outcome?

Bacteria in biofilms are often less susceptible to antimicrobial agents than the same bacteria in planktonic form. The MICRO is determined using planktonic bacteria and does not reflect the susceptibility of biofilm-associated bacteria. Biofilm-associated infections, such as prosthetic infections or catheter infections, may require higher drug concentrations or alternative therapy.

When should I consult an infectious disease specialist?

An infectious disease specialist should be consulted when the patient is not responding to the current therapy, when the infection is severe, or when the infection is at a complex site. The specialist can provide guidance on the interpretation of the MICRO and the PK/PD predictions, and the selection of alternative therapy. The consultation should be made when the clinical outcome is discordant with the MICRO result.

Using the Evidence

Source	Best use in this topic	Important limitation
Biosafety in Microbiological and Biomedical Laboratories	official guidance	Check the linked page for current local requirements
Microbiology Resources	official guidance	Check the linked page for current local requirements
Antimicrobial Resistance	official guidance	Check the linked page for current local requirements

Related Bacteriology Guides

References and Further Reading

Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
Microbiology Resources. American Society for Microbiology.
Antimicrobial Resistance. World Health Organization.
Bacteriological Analytical Manual. U.S. Food and Drug Administration.
Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
Culture Collections. American Type Culture Collection.
NCBI Pathogen Detection. National Center for Biotechnology Information.
When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.. 2026.
DeepTDM: Deep Learning-Based Prediction of Sequential Therapeutic Drug Monitoring Levels of Vancomycin.. 2025.
A multicentric, randomized, controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children-BENEFICIAL trial.. 2024.
Hybrid plasmids: genetic diversity and hypervirulent phenotype of &lt,i&gt,Klebsiella pneumoniae&lt,/i&gt,.. 2026.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.